- Home
- EARN vs FENC Comparison
EARN vs FENC Comparison
Compare EARN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- FENC
- Stock Information
- Founded
- EARN 2012
- FENC 1996
- Country
- EARN United States
- FENC United States
- Employees
- EARN N/A
- FENC N/A
- Industry
- EARN Real Estate Investment Trusts
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EARN Real Estate
- FENC Health Care
- Exchange
- EARN Nasdaq
- FENC Nasdaq
- Market Cap
- EARN 213.3M
- FENC 222.9M
- IPO Year
- EARN 2013
- FENC 2001
- Fundamental
- Price
- EARN $6.00
- FENC $8.67
- Analyst Decision
- EARN Buy
- FENC Strong Buy
- Analyst Count
- EARN 2
- FENC 2
- Target Price
- EARN $6.13
- FENC $13.00
- AVG Volume (30 Days)
- EARN 245.1K
- FENC 72.7K
- Earning Date
- EARN 08-11-2025
- FENC 08-12-2025
- Dividend Yield
- EARN 15.99%
- FENC N/A
- EPS Growth
- EARN N/A
- FENC N/A
- EPS
- EARN N/A
- FENC N/A
- Revenue
- EARN $35,893,000.00
- FENC $30,912,000.00
- Revenue This Year
- EARN $3.72
- FENC $0.85
- Revenue Next Year
- EARN $18.60
- FENC $55.16
- P/E Ratio
- EARN N/A
- FENC N/A
- Revenue Growth
- EARN 43.30
- FENC N/A
- 52 Week Low
- EARN $4.33
- FENC $3.96
- 52 Week High
- EARN $7.17
- FENC $9.30
- Technical
- Relative Strength Index (RSI)
- EARN 69.06
- FENC 60.19
- Support Level
- EARN $5.85
- FENC $8.47
- Resistance Level
- EARN $5.79
- FENC $8.96
- Average True Range (ATR)
- EARN 0.07
- FENC 0.36
- MACD
- EARN 0.02
- FENC -0.02
- Stochastic Oscillator
- EARN 91.25
- FENC 64.60
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.